| RNA interference in the clinic: challenges and future directions CV Pecot, GA Calin, RL Coleman, G Lopez-Berestein, AK Sood Nature Reviews Cancer 11 (1), 59-67, 2011 | 951 | 2011 |
| Paraneoplastic thrombocytosis in ovarian cancer RL Stone, AM Nick, IA McNeish, F Balkwill, HD Han, J Bottsford-Miller, ... New England Journal of Medicine 366 (7), 610-618, 2012 | 838 | 2012 |
| Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer D Yang, Y Sun, L Hu, H Zheng, P Ji, CV Pecot, Y Zhao, S Reynolds, ... Cancer cell 23 (2), 186-199, 2013 | 447 | 2013 |
| Tumour angiogenesis regulation by the miR-200 family CV Pecot, R Rupaimoole, D Yang, R Akbani, C Ivan, C Lu, S Wu, HD Han, ... Nature communications 4 (1), 2427, 2013 | 435 | 2013 |
| Hematogenous metastasis of ovarian cancer: rethinking mode of spread S Pradeep, SW Kim, SY Wu, M Nishimura, P Chaluvally-Raghavan, ... Cancer cell 26 (1), 77-91, 2014 | 337 | 2014 |
| Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles MMK Shahzad, LS Mangala, HD Han, C Lu, J Bottsford-Miller, ... Neoplasia 13 (4), 309-IN8, 2011 | 252 | 2011 |
| Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER T Van Den Beucken, E Koch, K Chu, R Rupaimoole, P Prickaerts, ... Nature communications 5 (1), 5203, 2014 | 234 | 2014 |
| Mediating passive tumor accumulation through particle size, tumor type, and location JL Perry, KG Reuter, JC Luft, CV Pecot, W Zamboni, JM DeSimone Nano letters 17 (5), 2879-2886, 2017 | 227 | 2017 |
| A Novel Platform for Detection of CK+ and CK− CTCs CV Pecot, FZ Bischoff, JA Mayer, KL Wong, T Pham, J Bottsford-Miller, ... Cancer discovery 1 (7), 580-586, 2011 | 222 | 2011 |
| Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer HS Kim, S Mendiratta, J Kim, CV Pecot, JE Larsen, I Zubovych, BY Seo, ... Cell 155 (3), 552-566, 2013 | 193 | 2013 |
| Role of focal adhesion kinase in regulating YB–1–mediated paclitaxel resistance in ovarian cancer Y Kang, W Hu, C Ivan, HJ Dalton, T Miyake, CV Pecot, B Zand, T Liu, ... Journal of the National Cancer Institute 105 (19), 1485-1495, 2013 | 183 | 2013 |
| Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression R Rupaimoole, SY Wu, S Pradeep, C Ivan, CV Pecot, KM Gharpure, ... Nature communications 5 (1), 5202, 2014 | 180 | 2014 |
| Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment M Nishimura, EJ Jung, MY Shah, C Lu, R Spizzo, M Shimizu, HD Han, ... Cancer discovery 3 (11), 1302-1315, 2013 | 178 | 2013 |
| Combining anti-miR-155 with chemotherapy for the treatment of lung cancers K Van Roosbroeck, F Fanini, T Setoyama, C Ivan, C Rodriguez-Aguayo, ... Clinical Cancer Research 23 (11), 2891-2904, 2017 | 147 | 2017 |
| KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism AV Vaseva, DR Blake, TSK Gilbert, S Ng, G Hostetter, SH Azam, ... Cancer cell 34 (5), 807-822. e7, 2018 | 142 | 2018 |
| A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer SY Wu, R Rupaimoole, F Shen, S Pradeep, CV Pecot, C Ivan, ... Nature communications 7 (1), 11169, 2016 | 135 | 2016 |
| Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers G Liu, D Yang, R Rupaimoole, CV Pecot, Y Sun, LS Mangala, X Li, P Ji, ... JNCI: Journal of the National Cancer Institute 107 (7), djv108, 2015 | 128 | 2015 |
| 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity SY Wu, X Yang, KM Gharpure, H Hatakeyama, M Egli, MH McGuire, ... Nature communications 5 (1), 3459, 2014 | 128 | 2014 |
| FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal M Haemmerle, J Bottsford-Miller, S Pradeep, ML Taylor, HJ Choi, ... The Journal of clinical investigation 126 (5), 1885-1896, 2016 | 118 | 2016 |
| Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity JJ Miret, P Kirschmeier, S Koyama, M Zhu, YY Li, Y Naito, M Wu, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 117 | 2019 |
